Intestinal epithelial cell tyrosine kinase 2 transduces IL-22 signals to protect from acute colitis

Journal of Immunology

Volumn 195, Issue 10, 2015, Pages 5011-5024

  Hainzl, Eva ^a   Stockinger, Silvia ^a   Rauch, Isabella ^b,c   Heider, Susanne ^d   Berry, David ^b   Lassnig, Caroline ^a   Schwab, Clarissa ^b   Rosebrock, Felix ^b   Milinovich, Gabriel ^b   Schlederer, Michaela ^d   Wagner, Michael ^b   Schleper, Christa ^b   Loy, Alexander ^b   Urich, Tim ^b   Kenner, Lukas ^a,d,e   Han, Xiaonan ^f   Decker, Thomas ^b   Strobl, Birgit ^a   Müller, Mathias ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE 1; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR; INTERLEUKIN RECEPTOR; RECOMBINANT INTERLEUKIN 22 FC; RECOMBINANT PROTEIN; RNA 16S; STAT3 PROTEIN; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; PROTEIN KINASE TYK2; STAT3 PROTEIN, MOUSE; TYK2 PROTEIN, MOUSE;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CITROBACTER RODENTIUM; COLITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; GENE TARGETING; IL 22 GENE; IMMUNOHISTOCHEMISTRY; IMMUNOSTIMULATION; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; RNA GENE; STAT3 GENE; WESTERN BLOTTING; ANIMAL; DEFICIENCY; ENTEROBACTERIACEAE INFECTION; GENETICS; HYPER IGE SYNDROME; IMMUNOLOGY; INTESTINE MUCOSA; KNOCKOUT MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CITROBACTER RODENTIUM; COLITIS; ENTEROBACTERIACEAE INFECTIONS; INTERLEUKINS; INTESTINAL MUCOSA; JOB SYNDROME; MICE; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TYK2 KINASE;

EID: 84958631189     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402565     Document Type: Article

References (66)

1. Strobl, B., D. Stoiber, V. Sexl, and M. Mueller. 2011. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front. Biosci. (Landmark Ed.) 16: 3214-3232.
2. Seto, Y., H. Nakajima, A. Suto, K. Shimoda, Y. Saito, K. I. Nakayama, and I. Iwamoto. 2003. Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. J. Immunol. 170: 1077-1083.
3. übel, C., A. Graser, S. Koch, R. J. Rieker, H. A. Lehr, M. Müller, and S. Finotto. 2014. Role of Tyk-2 in Th9 and Th17 cells in allergic asthma. Sci. Rep. 4: 5865.
4. Ishizaki, M., R. Muromoto, T. Akimoto, Y. Ohshiro, M. Takahashi, Y. Sekine, H. Maeda, K. Shimoda, K. Oritani, and T. Matsuda. 2011. Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Int. Immunol. 23: 575-582.
5. Ishizaki, M., R. Muromoto, T. Akimoto, Y. Sekine, S. Kon, M. Diwan, H. Maeda, S. Togi, K. Shimoda, K. Oritani, and T. Matsuda. 2014. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int. Immunol. 26: 257-267.
6. Kilic, S. S., M. Hacimustafaoglu, S. Boisson-Dupuis, A. Y. Kreins, A. V. Grant, L. Abel, and J. L. Casanova. 2012. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J. Pediatr. 160: 1055-1057.
7. Minegishi, Y., M. Saito, T. Morio, K. Watanabe, K. Agematsu, S. Tsuchiya, H. Takada, T. Hara, N. Kawamura, T. Ariga, et al. 2006. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25: 745-755.
8. Neurath, M. F. 2014. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14: 329-342.
9. Coskun, M., M. Salem, J. Pedersen, and O. H. Nielsen. 2013. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol. Res. 76: 1-8.
10. Rauch, I., E. Hainzl, F. Rosebrock, S. Heider, C. Schwab, D. Berry, D. Stoiber, M. Wagner, C. Schleper, A. Loy, et al. 2014. Type I interferons have opposing effects during the emergence and recovery phases of colitis. Eur. J. Immunol. 44: 2749-2760.
11. Rauch, I., F. Rosebrock, E. Hainzl, S. Heider, A. Majoros, S. Wienerroither, B. Strobl, S. Stockinger, L. Kenner, M. Müller, and T. Decker. 2015. Noncanonical effects of IRF9 in intestinal inflammation: more than type I and type III interferons. Mol. Cell. Biol. 35: 2332-2343.
12. Rauch, I., M. Müller, and T. Decker. 2013. The regulation of inflammation by interferons and their STATs. JAK-STAT 2: e23820.
13. Kamada, N., S. U. Seo, G. Y. Chen, and G. Núñez. 2013. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13: 321-335.
14. Maloy, K. J., and F. Powrie. 2011. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474: 298-306.
15. Vielnascher, R. M., E. Hainzl, N. R. Leitner, M. Rammerstorfer, D. Popp, A. Witalisz, R. Rom, M. Karaghiosoff, T. Kolbe, S. Müller, et al. 2014. Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance. Transgenic Res. 23: 519-529.
16. El Marjou, F., K. P. Janssen, B. H. Chang, M. Li, V. Hindie, L. Chan, D. Louvard, P. Chambon, D. Metzger, and S. Robine. 2004. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39: 186-193.
17. Teppner, I., B. Aigner, E. Schreiner, M. Müller, and M. Windisch. 2004. Polymorphic microsatellite markers in the outbred CFW and ICR stocks for the generation of speed congenic mice on C57BL/6 background. Lab. Anim. 38: 406-412.
18. Mähler Convenor, M., M. Berard, R. Feinstein, A. Gallagher, B. Illgen-Wilcke, K. Pritchett-Corning, and M. Raspa, FELASA working group on revision of guidelines for health monitoring of rodents and rabbits. 2014. FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units. Lab. Anim. 48: 178-192.
19. Wirtz, S., C. Neufert, B. Weigmann, and M. F. Neurath. 2007. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2: 541-546.
20. Ota, N., K. Wong, P. A. Valdez, Y. Zheng, N. K. Crellin, L. Diehl, and W. Ouyang. 2011. IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with Citrobacter rodentium. Nat. Immunol. 12: 941-948.
21. Berry, D., C. Schwab, G. Milinovich, J. Reichert, K. Ben Mahfoudh, T. Decker, M. Engel, B. Hai, E. Hainzl, S. Heider, et al. 2012. Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J. 6: 2091-2106.
22. Han, X., X. Ren, I. Jurickova, K. Groschwitz, B. A. Pasternak, H. Xu, T. A. Wilson, S. P. Hogan, and L. A. Denson. 2009. Regulation of intestinal barrier function by signal transducer and activator of transcription 5b. Gut 58: 49-58.
23. Han, X., B. Osuntokun, N. Benight, K. Loesch, S. J. Frank, and L. A. Denson. 2006. Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis. Am. J. Pathol. 169: 1999-2013.
24. Schwab, C., D. Berry, I. Rauch, I. Rennisch, J. Ramesmayer, E. Hainzl, S. Heider, T. Decker, L. Kenner, M. Müller, et al. 2014. Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery. ISME J. 8: 1101-1114.
25. Strobl, B., I. Bubic, U. Bruns, R. Steinborn, R. Lajko, T. Kolbe, M. Karaghiosoff, U. Kalinke, S. Jonjic, and M. Müller. 2005. Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J. Immunol. 175: 4000-4008.
26. Cash, H. L., C. V. Whitham, C. L. Behrendt, and L. V. Hooper. 2006. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 313: 1126-1130.
27. Mundy, R., T. T. MacDonald, G. Dougan, G. Frankel, and S. Wiles. 2005. Citrobacter rodentium of mice and man. Cell. Microbiol. 7: 1697-1706.
28. Wiles, S., S. Clare, J. Harker, A. Huett, D. Young, G. Dougan, and G. Frankel. 2004. Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium. Cell. Microbiol. 6: 963-972.
29. Gibson, D. L., M. Montero, M. J. Ropeleski, K. S. Bergstrom, C. Ma, S. Ghosh, H. Merkens, J. Huang, L. E. Mainsson, H. P. Sham, et al. 2010. Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling. Gastroenterology 139: 1277-1288.
30. Zhang, R., S. Gilbert, X. Yao, J. Vallance, K. Steinbrecher, R. Moriggl, D. Zhang, M. Eluri, H. Chen, H. Cao, et al. 2015. Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses. Pharmacol. Res. Perspect. 3: e00118.
31. Maxwell, J. R., and J. L. Viney. 2009. Overview of mouse models of inflammatory bowel disease and their use in drug discovery. Curr. Protoc. Pharmacol. Chapter 5: Unit 5.57. doi:10.1002/0471141755.ph0557s47.
32. Sugimoto, K. 2008. Role of STAT3 in inflammatory bowel disease. World J. Gastroenterol. 14: 5110-5114.
33. Ito, R., M. Shin-Ya, T. Kishida, A. Urano, R. Takada, J. Sakagami, J. Imanishi, M. Kita, Y. Ueda, Y. Iwakura, et al. 2006. Interferon-g is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. 146: 330-338.
34. Kühn, R., J. Löhler, D. Rennick, K. Rajewsky, and W. Müller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274.
35. Pickert, G., C. Neufert, M. Leppkes, Y. Zheng, N. Wittkopf, M. Warntjen, H. A. Lehr, S. Hirth, B. Weigmann, S. Wirtz, et al. 2009. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206: 1465-1472.
36. Cox, J. H., N. M. Kljavin, N. Ota, J. Leonard, M. Roose-Girma, L. Diehl, W. Ouyang, and N. Ghilardi. 2012. Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol. 5: 99-109.
37. Dudakov, J. A., A. M. Hanash, and M. R. van den Brink. 2015. Interleukin-22: immunobiology and pathology. Annu. Rev. Immunol. 33: 747-785.
38. Mizoguchi, A., and E. Mizoguchi. 2008. Inflammatory bowel disease, past, present and future: lessons from animal models. J. Gastroenterol. 43: 1-17.
39. Gerdes, J., H. Lemke, H. Baisch, H. H. Wacker, U. Schwab, and H. Stein. 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133: 1710-1715.
40. Zheng, Y., P. A. Valdez, D. M. Danilenko, Y. Hu, S. M. Sa, Q. Gong, A. R. Abbas, Z. Modrusan, N. Ghilardi, F. J. de Sauvage, and W. Ouyang. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14: 282-289.
41. Jostins, L., S. Ripke, R. K. Weersma, R. H. Duerr, D. P. McGovern, K. Y. Hui, J. C. Lee, L. P. Schumm, Y. Sharma, C. A. Anderson, et al; International IBD Genetics Consortium (IIBDGC). 2012. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491: 119-124.
42. Ishizaki, M., T. Akimoto, R. Muromoto, M. Yokoyama, Y. Ohshiro, Y. Sekine, H. Maeda, K. Shimoda, K. Oritani, and T. Matsuda. 2011. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J. Immunol. 187: 181-189.
43. Oyamada, A., H. Ikebe, M. Itsumi, H. Saiwai, S. Okada, K. Shimoda, Y. Iwakura, K. I. Nakayama, Y. Iwamoto, Y. Yoshikai, and H. Yamada. 2009. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J. Immunol. 183: 7539-7546.
44. Sugimoto, K., A. Ogawa, E. Mizoguchi, Y. Shimomura, A. Andoh, A. K. Bhan, R. S. Blumberg, R. J. Xavier, and A. Mizoguchi. 2008. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118: 534-544.
45. Zenewicz, L. A., G. D. Yancopoulos, D. M. Valenzuela, A. J. Murphy, S. Stevens, and R. A. Flavell. 2008. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29: 947-957.
46. Melgar, S., A. Karlsson, and E. Michaëlsson. 2005. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G1328-G1338.
47. Hildebrand, F., T. L. Nguyen, B. Brinkman, R. G. Yunta, B. Cauwe, P. Vandenabeele, A. Liston, and J. Raes. 2013. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. Genome Biol. 14: R4.
48. te Velde, A. A., M. I. Verstege, and D. W. Hommes. 2006. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm. Bowel Dis. 12: 995-999.
49. Smith, C. L., T. L. Arvedson, K. S. Cooke, L. J. Dickmann, C. Forte, H. Li, K. L. Merriam, V. K. Perry, L. Tran, J. B. Rottman, and J. R. Maxwell. 2013. IL-22 regulates iron availability in vivo through the induction of hepcidin. J. Immunol. 191: 1845-1855.
50. Zindl, C. L., J. F. Lai, Y. K. Lee, C. L. Maynard, S. N. Harbour, W. Ouyang, D. D. Chaplin, and C. T. Weaver. 2013. IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc. Natl. Acad. Sci. USA 110: 12768-12773.
51. Neufert, C., G. Pickert, Y. Zheng, N. Wittkopf, M. Warntjen, A. Nikolaev, W. Ouyang, M. F. Neurath, and C. Becker. 2010. Activation of epithelial STAT3 regulates intestinal homeostasis. Cell Cycle 9: 652-655.
52. Diegelmann, J., T. Olszak, B. Göke, R. S. Blumberg, and S. Brand. 2012. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and antiinflammatory proteins. J. Biol. Chem. 287: 286-298.
53. Lejeune, D., L. Dumoutier, S. Constantinescu, W. Kruijer, J. J. Schuringa, and J. C. Renauld. 2002. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J. Biol. Chem. 277: 33676-33682.
54. Rendon, J. L., X. Li, S. Akhtar, and M. A. Choudhry. 2013. Interleukin-22 modulates gut epithelial and immune barrier functions following acute alcohol exposure and burn injury. Shock 39: 11-18.
55. Collins, J. W., K. M. Keeney, V. F. Crepin, V. A. Rathinam, K. A. Fitzgerald, B. B. Finlay, and G. Frankel. 2014. Citrobacter rodentium: infection, inflammation and the microbiota. Nat. Rev. Microbiol. 12: 612-623.
56. Wittkopf, N., G. Pickert, U. Billmeier, M. Mahapatro, S. Wirtz, E. Martini, M. Leppkes, M. F. Neurath, and C. Becker. 2015. Activation of intestinal epithelial Stat3 orchestrates tissue defense during gastrointestinal infection. PLoS One 10: e0118401.
57. Brown, E. M., M. Sadarangani, and B. B. Finlay. 2013. The role of the immune system in governing host-microbe interactions in the intestine. Nat. Immunol. 14: 660-667.
58. Garrett, W. S., C. A. Gallini, T. Yatsunenko, M. Michaud, A. DuBois, M. L. Delaney, S. Punit, M. Karlsson, L. Bry, J. N. Glickman, et al. 2010. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8: 292-300.
59. Lupp, C., M. L. Robertson, M. E. Wickham, I. Sekirov, O. L. Champion, E. C. Gaynor, and B. B. Finlay. 2007. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2: 119-129.
60. Zenewicz, L. A., X. Yin, G. Wang, E. Elinav, L. Hao, L. Zhao, and R. A. Flavell. 2013. IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. J. Immunol. 190: 5306-5312.
61. Behnsen, J., S. Jellbauer, C. P. Wong, R. A. Edwards, M. D. George, W. Ouyang, and M. Raffatellu. 2014. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. Immunity 40: 262-273.
62. Eken, A., A. K. Singh, P. M. Treuting, and M. Oukka. 2014. IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol. 7: 143-154.
63. Willson, T. A., I. Jurickova, M. Collins, and L. A. Denson. 2013. Deletion of intestinal epithelial cell STAT3 promotes T-lymphocyte STAT3 activation and chronic colitis following acute dextran sodium sulfate injury in mice. Inflamm. Bowel Dis. 19: 512-525.
64. Lian, L. H., T. P. Lau, V. L. Lee, W. S. Lee, I. Hilmi, K. L. Goh, and K. H. Chua. 2013. Lack of association between TYK2 and STAT3 genes and Crohn's disease in the Malaysian population. Genet. Mol. Res. 12: 167-174.
65. Sohn, S. J., K. Barrett, A. Van Abbema, C. Chang, P. B. Kohli, H. Kanda, J. Smith, Y. Lai, A. Zhou, B. Zhang, et al. 2013. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J. Immunol. 191: 2205-2216.
66. Works, M. G., F. Yin, C. C. Yin, Y. Yiu, K. Shew, T. T. Tran, N. Dunlap, J. Lam, T. Mitchell, J. Reader, et al. 2014. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J. Immunol. 193: 3278-3287.